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CsA  short Mtx. Patients were grafted with a median number
of 7  106/kg CD34 cells (range: 1.5-31  106/kg) and 1.7 
104 CD3 cells (range: 0.4-5.9  104/kg). All patients engrafted
and achieved mixed chimerism. Median time to neutrophil and
platelet engraftment was 12 days (range: 9-15 days) and 12 days
(range: 8-24 days), respectively. DLI of 0.5  105/kg CD3
cells were scheduled on day 15, 30 and 60. A total of 46
DLI were performed. The median follow-up for survivors is 6
months (range: 3-16 months). No patient developed acute
GvHD grade 2 or higher and one developed chronic GvHD.
One patient died on day 12 due to engraftment syndrome.
The probability of TRM was 6% (95% CI; 2%-10%). Another
patient died of relapsed disease on day 70. The probability of
relapse was 7% (95% CI; 2%-12%).The DFS is 87% (95% CI;
78%- 96%).The preliminary results of our transplantation strat-
egy are encouraging. A large prospective study is needed to
substantiate these results.
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EARLY DONOR LYMPHOCYTE INFUSION (DLI) DOES NOT CONSIS-
TENTLY PREVENT GRAFT REJECTION IN DOGS GIVEN DLA-IDENTICAL
MARROWS AFTER 1 Gy TOTAL BODY IRRADIATION (TBI)
Baron, F., Sandmaier, B., Zellmer, E., Sorror, M., Little, M.T.,
Storb, R. Fred Hutchinson Cancer Research Center, Seattle, WA.
Background: Secondary graft rejections may occur after non-
myeloablative conditioning for hematopoietic cell transplanta-
tion (HCT), particularly in patients with chronic myeloid leu-
kemia given unrelated grafts (Biol Blood Marrow Transplant.
2005;11:272). We have shown that low (50%) donor T-cell
and NK cell chimerism levels on day 14 after HCT predicted
graft rejection (Blood. 2004;104:2254). Here we investigated in a
pre-clinical canine model of HCT, whether pre-emptive DLI
given 1 month after HCT could prevent secondary graft rejec-
tion that was the rule in dogs given DLA-identical marrow after
suboptimal conditioning with 1 Gy TBI and postgrafting im-
munosuppression with cyclosporine (CSP) combined with ei-
ther mycophenolate mofetil (MMF) or rapamycin (11 of 11 dogs
experienced graft rejection by wk 12). Methods: 9 dogs were
given DLA-identical marrow grafts after 1 Gy TBI followed by
postgrafting immunosuppression with MMF (days 0-27) and
CSP (started on day 1 and discontinued 1 day before DLI). A
single DLI (containing 1.0-2.3  108 T-cells/kg) was given
28-36 days after HCT in each dogs. In addition, 5 of 9 dogs
received pentostatin, 4 mg/m2 given 2 days before DLI (n  3);
or 4 mg/m2/day on days 4-2 before DLI (n  2) (Table 1).
Presence of donor cells in peripheral blood mononuclear cells
(PBMC) was assessed by VNTR-PCR. The endpoint of the
study was persistence of mixed donor/host chimerism at 30 wks.
Results: Marrow cell numbers were similar in DLI and histor-
ical dogs (medians 3.6  108and 4.0  108 nucleated cells/kg,
respectively, P  .20). Two of the ﬁrst 4 dogs given DLI only
were mixed donor-host chimeras at 30 wks, while 2 rejected
their grafts on wks 10 and 15, respectively. We then investigated
in 5 dogs whether host immunosuppression with pentostatin
prior to DLI could overcome the pending rejection and increase
the efﬁcacy of DLI. Three of the 5 dogs (including 1 of the 2
given 3 doses of pentostatin) rejected their grafts on wks 8, 12
and 16 after HCT, respectively, while 1 was a stable mixed
donor/host chimera 24 wks after HCT, and 1 was too early to be
evaluated. The 30-wk probability of sustained donor engraft-
ment was 37.5% in dogs given DLI, versus 0% in historical dogs
(P  .01). Conclusions: DLI, with or without preceding pen-
tostatin, was effective in one third of dogs studied to prevent
graft rejection. The model might be useful to develop further
strategies aimed at preventing graft rejection in patients with
low chimerism (Table 1).
Table 1. Results
Dog # Pentostatin?
% Donor
Chimerism in
PBMC before DLI
Duration of Mixed
Chimerism in wks
(Final % of Donor
Chimerism in PBMC)
1 No 40 >30 (54)
2 No 13.1 10 (0)
3 No 7.7 15 (0)
4 No 12.4 >30 (5)
5 4 mg/m2 23.1 16 (0)
6 4 mg/m2 20.5* 12 (0)
7 4 mg/m2 16.2 >24 (14.4)
8 3  4 mg/m2 9.9 8 (0)
9 3  4 mg/m2 Too early Too early
*4 days after DLI.
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EX VIVO EXPANDED T REGULATORY (TREG) CELLS BLOCK THE BREAK-
ING OF TOLERANCE IN MIXED CHIMERAS
Lesnikova, M.1, Nikitine, A.1, Mason, N.2, Storb, R.F.1,3,
Nash, R.A.1,3, Georges, G.E.1,3 1. Fred Hutchinson Cancer Research
Center, Seattle, WA; 2. University of Pennsylvania, Philadelphia, PA;
3. University of Washington, Seattle, WA.
Nonmyeloablative allogeneic hematopoietic cell transplantation
(HCT) consisting of 2 Gray (Gy) total body irradiation (TBI), dog
leukocyte antigen-identical marrow, and short-term postgrafting im-
munosuppression with cyclosporine and mycophenolate mofetil was
developed in the dog model as an effective way to establish long-term,
stable mixed hematopoietic chimerism. We hypothesized that Treg
cells are crucial to maintaining stable mixed chimerism. All dogs in the
current study were stable mixed chimeras established as described.
Previously, we showed in 8 mixed chimeras that naive DLI did not
change the percent donor chimerism. We asked if reconditioning
mixed chimeras with a nonmyeloablative dose of 2 Gy TBI followed
by DLI could increase donor chimerism. Seven mixed chimeras were
re-conditioned with 2 Gy TBI followed by DLI (median dose, 1.5 
108CD3/kg). Within 4 weeks after DLI, conversion to 100% donor
chimerism was seen in 5 of 7 dogs and 2 dogs had a 	50% sustained
increase in donor chimerism. A control group of 3 mixed chimeras
reconditioned with 2 Gy TBI without DLI had no change in donor
chimerism. These results show that reconditioning with 2 Gy TBI
followed by DLI can break the tolerance mechanism established in
mixed chimeras. Next, we asked if CD4CD25 Treg cells obtained
from mixed chimeras prior to reconditioning could block the increase
in donor chimerism following 2 Gy TBI and DLI. Peripheral blood
mononuclear cells (PBMC) were obtained from mixed chimeras by
leukapheresis and were activated with 3rd party irradiated PBMC and
CD34 derived dendritic cells. On day 4 of culture, CD25 cells were
isolated by immunomagnetic selection. Artiﬁcial antigen presenting
cells (aAPC) were added to expand the CD4CD25 Treg cells. The
aAPC expressed CD32, CD86, and IL-15, and were loaded with
mitogenic anti-CD3 antibody. After 10 days, CD4CD25 Treg
cells had expanded a median of 23-fold and inhibited MLR. To date,
Treg were generated from 4 mixed chimeric dogs and were infused
back into the respective mixed chimera (median cell dose, 1.0 
107/kg) after reconditioning with 2 Gy TBI and immediately prior to
DLI. In 3 of 4 dogs, there was no signiﬁcant change in donor
chimerism after 12-16 weeks and 1 dog converted to complete donor
chimerism within 6 weeks. These preliminary results suggest that ex
vivo expanded CD4CD25 Treg cells have in vivo function and can
restore the tolerance mechanism in mixed chimeras that is broken by
2 Gy TBI and DLI.
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